Table 1.

Study designs for phase 3 galcanezumab studies in patients with episodic and chronic migraine.

Study name	Migraine population	Active treatment period*	Number randomized
			Placebo	Galcanezumab120 mg+/240 mg
REGAIN	Chronic	3-month double-blind, placebo-controlled, followed by optional 9-month open-label period†	558	278/277
EVOLVE-1	Episodic	6-month double-blind, placebo-controlled	433	213/212
EVOLVE-2	Episodic	6-month double-blind, placebo-controlled	461	231/223
Study CGAJ	Episodic or chronic	12-month open-label	–	135/135

Notes:

^*The active treatment period of all four studies was followed by a 4-month post-treatment follow-up (washout) period.

⁺Patients randomized to the 120 mg arm received an initial loading dose of 240 mg.

^†The open-label extension and follow-up periods of REGAIN were ongoing at the time of these analyses.